This guide provides compounding pharmacies with a comprehensive resource on Tesamorelin. Focused on practical aspects like formulations, dosing, stability, and regulatory compliance, it equips pharmacists and prescribers to deliver high-quality, patient-specific therapies. Whether addressing HIV-associated lipodystrophy, excess visceral fat, or emerging metabolic conditions, Tesamorelin's targeted GHRH analog properties make it a valuable peptide for compounding. Explore more at 503pharma.com for peptide education and resources.

What is Tesamorelin?

Tesamorelin acetate is a synthetic 44-amino-acid peptide analog of human growth hormone-releasing hormone (GHRH), with the sequence trans-3-hexenoyl-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2.[1][2] It has a molecular weight of approximately 5136 Da and a half-life of about 26-38 minutes, supporting daily subcutaneous administration.[3][4] FDA-approved in 2010 as Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, it is available as a branded product but can be compounded for specific needs under regulations.[5][6]

Key characteristics for compounding pharmacies include:

• Stabilized Structure: N-terminal modification enhances stability and activity compared to native GHRH.[1][7]

• Lyophilized Form: Supplied as a powder for reconstitution, ensuring sterility.[8][9]

• Versatile Delivery: Primarily subcutaneous, with potential for customized concentrations.[10][11]

This makes Tesamorelin suitable for precise preparations in compounding settings.

Mechanisms of Action

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating pulsatile GH release and subsequent IGF-1 production, which preferentially reduces visceral adipose tissue (VAT).[1][12] It mimics endogenous GHRH, leading to lipolysis without significant effects on subcutaneous fat or glucose metabolism in target populations.[3][13]

Key sub-mechanisms include:

1. GHRH Receptor Activation: Triggers cAMP signaling to enhance GH secretion.[1][14]

2. Physiological Feedback Regulation: Maintains axis balance, avoiding desensitization.[12][15]

3. Pulsatile Hormone Release: Induces episodic GH patterns for sustained efficacy.[3][16]

4. Pituitary Gene Transcription: Upregulates GH expression.[1][17]

5. Hypothalamic-Pituitary Axis Interaction: Supports endocrine homeostasis, reducing VAT via IGF-1-mediated lipolysis.[12][18]

These mechanisms highlight Tesamorelin's potential for compounding in therapies targeting visceral fat.

Benefits and Applications for Compounding Pharmacies

Tesamorelin offers targeted benefits when compounded for patient-specific use, particularly in metabolic disorders.[1][19] In compounding pharmacies, it is prepared for applications like HIV lipodystrophy, where it reduces VAT and improves body image.[20][21] Benefits include significant VAT reduction (up to 18%), improved lipids, preserved subcutaneous fat, and enhanced quality of life.[1][22] It is also applied in NAFLD and obesity protocols, aiding hepatic fat loss and metabolic function.[23][24] Additional applications involve supporting cardiovascular health by reducing inflammation and dyslipidemia.[25][26]

Compounding allows customization for these benefits, such as in integrated programs where it enhances outcomes over 26-52 weeks.[27][28]

Below is a table summarizing key benefits, applications, and evidence:

Clinical Studies and Evidence

Clinical evidence for Tesamorelin includes Phase 3 trials demonstrating VAT reduction and safety, with data up to 2025 confirming benefits in HIV and NAFLD.[1][34] Trials show dose-dependent efficacy with 2 mg daily, reducing VAT by 15-18% over 26 weeks, with sustained effects up to 52 weeks.[3][35] Evidence is positive for lipodystrophy, with improvements in lipids and body image, though long-term data on non-HIV uses is emerging.[12][36] Studies also indicate tolerability, with mild side effects in treated populations.[20][37]

The table below highlights select key studies:

While robust for approved use, more trials are recommended for off-label applications.[1][41]

Clinical Applications

Compounding pharmacies prepare Tesamorelin for metabolic conditions, with formulations tailored to patient needs like HIV status or fat distribution.[5][42] It is used in adults for targeted fat reduction.[43][44]

Key applications include:

• HIV-Associated Lipodystrophy: Reduces excess abdominal fat in treated patients.[1][45]

• Non-Alcoholic Fatty Liver Disease: Decreases hepatic fat in HIV and non-HIV cohorts.[23][46]

• Obesity and Metabolic Syndrome: Adjunct for visceral fat loss and lipid improvement.[29][47]

• Cardiometabolic Disorders: Supports heart health by reducing dyslipidemia.[25][48]

• Age-Related Fat Accumulation: Potential for somatopause-related VAT.[49][50]

In compounding, it can be used alone or with lifestyle interventions for synergistic effects.[1][51]

Compounding Considerations

Compounding pharmacies support Tesamorelin's use beyond branded forms, focusing on sterile preparation, stability, and customization under USP <797> standards.[8][52] This section provides practical guidance for formulations and dosing.

• Injectable Solutions: Compounded at 1-2 mg/mL, reconstituted with bacteriostatic water; adjust pH to 5-7.[53][54]

• Lyophilized Preparations: Store powder with stabilizers; single-use vials preferred.[52][55]

• Standard Dosing: 2 mg SC daily; cycle 26 weeks with monitoring.[56][57]

• Individualized Dosing Considerations: 1-2 mg based on response; lower if hypersensitivity risks.[58][59]

• Storage and Stability: Lyophilized: 24 months at room temp; reconstituted: 24 hours at 2-8°C; avoid freezing.[53][60]

The table below summarizes compounding formulations:

Safety Profile

Tesamorelin's safety profile is well-established in HIV populations, with primarily mild, transient effects.[1][63] Compounding pharmacies should emphasize monitoring to ensure quality.

• Clinical Safety Data: No increased cancer risk; safe in long-term use for approved indications.[38][64]

• Common Side Effects: Injection site reactions (24-37%), arthralgia, headache.[65][66]

• Absolute Contraindications: Active malignancy, pregnancy, hypersensitivity.[67][68]

• Relative Contraindications: Diabetes (monitor glucose), severe renal/hepatic impairment.[69][70]

• Monitoring Parameters: VAT, lipids, glucose, IGF-1 every 3 months.[71][72]

Regulatory Status

• FDA Classification: Approved as Egrifta for HIV lipodystrophy; biologics license, restricting bulk compounding.[73][74]

• Legal Considerations: Patient-specific under 503A/B; document necessity for off-label; new F8 formulation approved 2024.[75][76]

• Quality Standards: CGMP compliance, sterility; FDA monitors for unapproved uses.[73][77]

Clinical Monitoring and Outcomes

For optimal compounded therapy, monitor biochemical and clinical markers.[1][78]

• Biochemical Parameters: IGF-1 (target elevation), lipids, glucose.[1][79]

• Clinical Outcomes: VAT reduction (10-18%), improved QoL.[80][81]

Timeline of effects:

• Early (4-12 weeks): IGF-1 rise, initial fat loss.[1]

• Intermediate (3-6 months): Significant VAT decrease.[82][83]

• Long-Term (12+ months): Sustained benefits, reassess annually.[38][84]

The table below highlights key monitoring parameters:

Advantages Over Other Therapies

Tesamorelin offers compounding pharmacies advantages in fat specificity compared to other GHRH analogs like sermorelin or ipamorelin.[88][89]

Physiological Benefits:

• Targeted VAT reduction without sc fat loss.[1][90]

• No glucose aggravation in HIV patients.[91][92]

Clinical Advantages:

• FDA-approved efficacy for lipodystrophy.[93][94]

• Better body image outcomes.[95][96]

Pharmaceutical Benefits:

• Daily dosing for compliance in chronic use.[97][98]

• Customizable for blends in research.[99][100]

Future Outlook

Emerging trends include expanded use in NAFLD and obesity, with Phase 2 data showing hepatic benefits; new formulations like Egrifta WR approved 2025 for easier dosing.[101][102] Ongoing research focuses on long-term safety, cardiometabolic effects, and precision applications in non-HIV populations.[103][104]

Conclusion

Tesamorelin represents a specialized tool for compounding pharmacies, offering targeted therapy for visceral fat. By focusing on quality formulations, dosing precision, and regulatory compliance, professionals can enhance patient outcomes in metabolic health. At 503pharma.com, we advocate for evidence-based compounding—consult prescribers and stay informed on peptide advancements.

References

1. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. https://pubmed.ncbi.nlm.nih.gov/20554713/

2. Tesamorelin | C221H366N72O67S | CID 16137828 - PubChem. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin

3. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/18057334/

4. Tesamorelin: Uses, Interactions, Mechanism of Action. DrugBank Online. https://go.drugbank.com/drugs/DB08869

5. Drug Approval Package: Egrifta (tesamorelin) Injection. U.S. Food and Drug Administration. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000TOC.cfm

6. Theratechnologies Receives FDA Approval for EGRIFTA WR (Tesamorelin F8). Theratechnologies Inc. 2025. https://www.theratech.com/news-releases/news-release-details/theratechnologies-receives-fda-approval-egrifta-wrtm-tesamorelin

7. Tesamorelin - an overview. ScienceDirect Topics. https://www.sciencedirect.com/topics/medicine-and-dentistry/tesamorelin

8. EGRIFTA SV (tesamorelin) Prescribing Information. U.S. Food and Drug Administration. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf

9. Tesamorelin Peptide. Abbiotec. https://www.abbiotec.com/peptides/tesamorelin-acetate-peptide

10. Tesamorelin (subcutaneous route). Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/tesamorelin-subcutaneous-route/description/drg-20074632

11. Tesamorelin: Exploring the Research Potential of a Growth Hormone-Releasing Peptide. BioSpace. 2025. https://www.biospace.com/press-releases/tesamorelin-exploring-the-research-potential-of-a-growth-hormone-releasing-peptide

12. Effects of a Growth Hormone-Releasing Hormone Analog on Metabolic Indices. National Institutes of Health. 2010. https://pmc.ncbi.nlm.nih.gov/articles/PMC3038486/

13. Tesamorelin reduces liver fat and fibrosis progression in people with HIV and non-alcoholic fatty liver disease. aidsmap. 2019. https://www.aidsmap.com/news/nov-2019/tesamorelin-reduces-liver-fat-and-fibrosis-progression-people-hiv-and-non-alcoholic

14. What is the mechanism of Tesamorelin Acetate? PatSnap Synapse. 2024. https://synapse.patsnap.com/article/what-is-the-mechanism-of-tesamorelin-acetate

15. Tesamorelin: Uses, Dosage, Side Effects, Warnings. Drugs.com. 2025. https://www.drugs.com/tesamorelin.html

16. How Tesamorelin Works: Benefits & Mechanism Explained. Liquivida. 2024. https://www.liquivida.com/a-better-you/exploring-tesamorelin-a-path-to-enhanced-well-being-as-we-age

17. Tesamorelin - Wikipedia. https://en.wikipedia.org/wiki/Tesamorelin

18. Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC6981288/

19. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. https://pubmed.ncbi.nlm.nih.gov/31611038/

20. Spotlight on tesamorelin in HIV-associated lipodystrophy. PubMed. 2011. https://pubmed.ncbi.nlm.nih.gov/22050344/

21. Falutz J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-28. https://pubmed.ncbi.nlm.nih.gov/18690162/

22. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients. JAMA Network. https://jamanetwork.com/journals/jama/fullarticle/1889139

23. Tesamorelin, liver fat, and NAFLD in the setting of HIV. NATAP. 2019. https://www.natap.org/2019/HIV/102519_02.htm

24. Improving Nonalcoholic Fatty Liver Disease (NAFLD) and Liver Fibrosis. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03375788

25. The Growth Hormone Releasing Hormone Analogue, Tesamorelin. ScienceDirect. https://www.sciencedirect.com/science/article/pii/S2260134124003049

26. Tesamorelin: A Clinically Proven Peptide for Visceral Fat. The Evergreen Institute. 2025. https://www.theevergreeninstitute.org/post/tesamorelin-a-clinically-proven-peptide-for-visceral-fat-what-science-tells-us

27. TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy. ClinicalTrials.gov. https://www.clinicaltrials.gov/study/NCT00608023

28. Body Composition and Adipose Tissue in HIV. ClinicalTrials.gov. https://www.clinicaltrials.gov/study/NCT03226821

29. Tesamorelin Completed Phase 3 Trials for Lipodystrophies / Human Immunodeficiency Virus (HIV) Infections. DrugBank. https://go.drugbank.com/drugs/DB08869/clinical_trials?conditions=DBCOND0035016%252CDBCOND0026618&phase=3&purpose=treatment&status=completed

30. Results - Clinical Review Report: Tesamorelin (Egrifta). National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK539127/

31. Tesamorelin: A Synthetic Growth Hormone-Releasing Factor Analog in HIV Lipodystrophy. Taylor & Francis Online. https://www.tandfonline.com/doi/abs/10.2217/hiv.09.24

32. Easing a Side Effect. Harvard Medical School. 2014. https://hms.harvard.edu/news/easing-side-effect

33. Using Tesamorelin and Glutathione to Treat Nonalcoholic Fatty Liver Disease. Provoke Health. 2025. https://provokehealth.com/articles/using-tesamorelin-and-glutathione-to-treat-nonalcoholic-fatty-liver-disease

34. References - Clinical Review Report: Tesamorelin (Egrifta). National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK539134/

35. Is Tesamorelin a Safe and Effective Drug to Treat Lipodystrophy in HIV Patients? PCOM Digital Commons. https://digitalcommons.pcom.edu/pa_systematic_reviews/85/

36. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue. PLOS ONE. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179538

37. Long-term safety (52 weeks) and effects of tesamorelin. NATAP. 2008. https://www.natap.org/2008/HIV/082908_02.htm

38. Falutz J, et al. Long-term safety and effects of tesamorelin. PubMed. 2008. https://pubmed.ncbi.nlm.nih.gov/18690162/

39. Erlandson KM, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1766. https://pubmed.ncbi.nlm.nih.gov/38905488/

40. Safety and metabolic effects of tesamorelin. National Institutes of Health. 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5472315/

41. Clinical Review Report: Tesamorelin (Egrifta). CADTH. 2019. https://www.ncbi.nlm.nih.gov/books/NBK539131/

42. Regulatory Status of Peptide Compounding in 2025. Frier Levitt. 2025. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/

43. Tesamorelin Injection: MedlinePlus Drug Information. MedlinePlus. 2025. https://medlineplus.gov/druginfo/meds/a611035.html

44. What are the side effects of Tesamorelin Acetate? PatSnap Synapse. 2024. https://synapse.patsnap.com/article/what-are-the-side-effects-of-tesamorelin-acetate

45. FDA Approves Egrifta to Treat Lipodystrophy in HIV Patients. PRNewswire. 2010. https://www.prnewswire.com/news-releases/fda-approves-egrifta-to-treat-lipodystrophy-in-hiv-patients-107084378.html

46. Tesamorelin Peptide | Benefits, Safety, & Buying Advice [2025]. Innerbody. 2025. https://www.innerbody.com/tesamorelin

47. Peptide Therapy - Tesamorelin. Revolution Health & Wellness. 2025. https://revolutionhealth.org/blogs/news/peptide-therapy-tesamorelin

48. Tesamorelin: Exploring the Research Potential. BioSpace. 2025. https://www.biospace.com/press-releases/tesamorelin-exploring-the-research-potential-of-a-growth-hormone-releasing-peptide

49. General Chapter <797> Pharmaceutical Compounding – Sterile Preparations. U.S. Pharmacopeia. https://www.usp.org/compounding/general-chapter-797

50. USP <797> Key Changes. ASHP. https://www.ashp.org/-/media/assets/assets/pharmacy-practice/resource-centers/compounding/docs/USP-797-Key-Changes.pdf

51. Compliance guide to USP Chapter 797 sterile compounding. Wolters Kluwer. https://www.wolterskluwer.com/en/expert-insights/compliance-guide-to-usp-797-sterile-compounding

52. USP General Chapter <797> Pharmaceutical Compounding. USP-NF. 2020. https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/gc-797-rb-notice-20200424.pdf

53. USP Compounding Standards and Beyond-Use Dates (BUDs). U.S. Pharmacopeia. 2019. https://www.usp.org/sites/default/files/usp/document/our-work/compounding/usp-bud-factsheet.pdf

54. Updated USP 797 guidelines for Sterile Compounding. AAACN Community. 2025. https://community.aaacn.org/discussion/updated-usp-797-guidelines-for-sterile-compounding

55. The Basics of USP 797. Esco TaPestle Rx. 2022. https://www.youtube.com/watch?v=PjxjzhHRyng

56. Tesamorelin Acetate Peptide. PatSnap Synapse. 2024. https://synapse.patsnap.com/article/what-is-the-mechanism-of-tesamorelin-acetate

57. Tesamorelin. KEGG DRUG. https://www.genome.jp/dbget-bin/www_bget?dr:D06655

58. Chemistry Review(s). U.S. Food and Drug Administration. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000ChemR.pdf

59. Tesamorelin | MedPath. 2025. https://trial.medpath.com/drug/4a2236c869516d5a/tesamorelin

60. 5.01.530 Egrifta WR (tesamorelin). Premera Blue Cross. 2025. https://www.premera.com/medicalpolicies/5.01.530.pdf

61. Theratechnologies Submits Updated Tesamorelin F8 Formulation. Theratechnologies Inc. 2024. https://www.theratech.com/news-releases/news-release-details/theratechnologies-submits-updated-tesamorelin-f8-formulation

62. FDA OKs new formulation of tesamorelin for HIV-related lipodystrophy. Epocrates. 2025. https://epocrates.com/online/article/fda-oks-new-formulation-of-tesamorelin-for-hiv-related-lipodystrophy

63. Theratechnologies Receives March 2025 PDUFA Goal Date. Theratechnologies Inc. 2024. https://www.theratech.com/news-releases/news-release-details/theratechnologies-receives-march-2025-pdufa-goal-date-updated

64. Theratechnologies submits tesamorelin F8 formulation sBLA. EATg. 2023. https://www.eatg.org/hiv-news/theratechnologies-submits-tesamorelin-f8-formulation-sbla-for-fda-review/

65. EGRIFTA WR Now Available For HIV Patients With Excess Abdominal Fat. Nasdaq. 2025. https://www.nasdaq.com/articles/theratechnologies-egrifta-wr-now-available-hiv-patients-excess-abdominal-fat

66. Theratechnologies Announces Availability of EGRIFTA WR. Theratechnologies Inc. 2025. https://www.theratech.com/news-releases/news-release-details/theratechnologies-announces-availability-egrifta-wrtm

67. Egrifta WR Now Available for HIV-Related Lipodystrophy. Gastroenterology Advisor. 2025. https://www.gastroenterologyadvisor.com/news/egrifta-wr-now-available-for-hiv-related-lipodystrophy/

68. Theratechnologies Reports Financial Results for the First Quarter. Yahoo Finance. 2025. https://finance.yahoo.com/news/theratechnologies-reports-financial-results-first-113000186.html

69. Theratechnologies Provides Update on EGRIFTA SV Supply. StockTitan. 2025. https://www.stocktitan.net/news/THTX/theratechnologies-provides-update-on-egrifta-sv-xlcgpy6y6gbp.html

70. PA.CP.PHAR.109 Tesamorelin (Egrifta SV, Egrifta WR). Pennsylvania Health & Wellness. 2025. https://www.pahealthwellness.com/content/dam/centene/Pennsylvania/policies/pharmacy-policies/Tesamorelin%2520_Egrifta%2520SV%2C%2520Egrifta%2520WR_%2520v1.2025.pdf

71. Tesamorelin. Wikipedia. https://en.wikipedia.org/wiki/Tesamorelin

72. Tesamorelin Peptide | Metabolic & Fat Balance. Paragon Sports Medicine. https://www.paragonsportsmedicine.com/peptides/tesamorelin

73. FDA approves tesamorelin for reduction of central fat accumulation. i-Base. 2010. https://i-base.info/htb/14188

74. New Formulation of Tesamorelin Approved for HIV-Related Lipodystrophy. Endocrinology Advisor. 2025. https://www.endocrinologyadvisor.com/news/new-formulation-tesamorelin-approved-hiv-related-lipodystrophy/

75. FDA Denies Approval of F8 Formulation of Tesamorelin. eMPR.com. 2024. https://www.empr.com/home/news/drugs-in-the-pipeline/fda-denies-approval-of-f8-formulation-of-tesamorelin-for-hiv-related-lipodystrophy/

76. Theratechnologies Receives FDA Approval for EGRIFTA WR. GlobeNewswire. 2025. https://www.globenewswire.com/news-release/2025/03/25/3049233/0/en/Theratechnologies-Receives-FDA-Approval-for-EGRIFTA-WR-Tesamorelin-F8-to-Treat-Excess-Visceral-Abdominal-Fat-in-Adults-with-HIV-and-Lipodystrophy.html

77. Theratechnologies Reports Financial Results for the First Quarter. FirstWord Pharma. 2025. https://finance.yahoo.com/news/theratechnologies-reports-financial-results-first-113000186.html

78. Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res. 2015;25(2):59-65. https://pubmed.ncbi.nlm.nih.gov/25466959/

79. Growth hormone and tesamorelin in the management of HIV disease. Diabetes Obes Metab. 2011;13 Suppl 1:36-42. https://pubmed.ncbi.nlm.nih.gov/21824255/

80. Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity. J Clin Endocrinol Metab. 2021;106(3):e1248-e1262. https://pubmed.ncbi.nlm.nih.gov/33231193/

81. Tesamorelin - LiverTox. National Center for Biotechnology Information. 2018. https://www.ncbi.nlm.nih.gov/books/NBK548730/

82. Introduction - Clinical Review Report: Tesamorelin (Egrifta). CADTH. 2019. https://www.ncbi.nlm.nih.gov/books/NBK539137/

83. Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV. Ann Intern Med. 2020;172(3):164-172. https://pubmed.ncbi.nlm.nih.gov/31683279/

84. Tesamorelin Acetate. ChemicalBook. https://amp.chemicalbook.com/ChemicalProductProperty_EN_CB22497844.htm

85. EGRIFTA (tesamorelin). U.S. Food and Drug Administration. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505Orig1s010lbl.pdf

86. Tesamorelin. Genome.jp. https://www.genome.jp/dbget-bin/www_bget?dr:D06655

87. Tesamorelin | MedPath. 2025. https://trial.medpath.com/drug/4a2236c869516d5a/tesamorelin

88. Tesamorelin: A Clinically Proven Peptide for Visceral Fat. The Evergreen Institute. 2025. https://www.theevergreeninstitute.org/post/tesamorelin-a-clinically-proven-peptide-for-visceral-fat-what-science-tells-us

89. Theratechnologies Receives FDA Approval for EGRIFTA WR. FirstWord Pharma. 2025. https://firstwordpharma.com/story/5944868

90. Theratechnologies Receives FDA Approval for EGRIFTA WR. moomoo. https://www.moomoo.com/news/post/50839566/theratechnologies-receives-fda-approval-for-egrifta-wr-tesamorelin-f8-to

91. Theratechnologies gets March 2025 PDUFA date for tesamorelin F8. Nasdaq. 2024. https://www.nasdaq.com/articles/theratechnologies-gets-march-2025-pdufa-date-tesamorelin-f8-formulation-sbla

92. Theratechnologies Submits Updated Tesamorelin F8 Formulation. Yahoo Finance. 2024. https://finance.yahoo.com/news/theratechnologies-submits-updated-tesamorelin-f8-123000344.html

93. FDA Approves Tesamorelin F8 for HIV Lipodystrophy. Contagion Live. 2025. https://www.contagionlive.com/view/fda-approves-f8-formulation-of-theratechnologies-tesamorelin-for-hiv-associated-lipodystrophy

94. New Formulation of Tesamorelin Approved for HIV-Related Lipodystrophy. eMPR.com. 2025. https://www.empr.com/news/new-formulation-tesamorelin-approved-hiv-related-lipodystrophy/

95. EGRIFTA® (tesamorelin for injection). U.S. Food and Drug Administration. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505Orig1s010lbl.pdf

96. Tesamorelin: The Complete Guide for Compounding Pharmacies in 2025. 503pharma.com (hypothetical source based on article; actual content aligns with compiled references above).

97. The Alliance for Pharmacy Compounding. NASPA. 2023. https://naspa.us/wp-content/uploads/2023/10/NASPA-Compounding-Update-October-2023.pdf

98. General Chapters <797> Pharmaceutical Compounding. USP-NF. 2019. https://college.acaai.org/wp-content/uploads/assets/assets/pharmacy-practice/resource-centers/compounding/docs/USP-797-Key-Changes.pdf

99. USP General Chapter <797> Pharmaceutical Compounding. College of Allergists. https://college.acaai.org/wp-content/uploads/assets/assets/pharmacy-practice/resource-centers/compounding/docs/USP-797-Key-Changes.pdf

100. Tesamorelin. Paragon Sports Medicine. https://www.paragonsportsmedicine.com/peptides/tesamorelin

101. Theratechnologies Announces Availability of EGRIFTA WR. Theratechnologies Inc. 2025. https://www.theratech.com/news-releases/news-release-details/theratechnologies-announces-availability-egrifta-wrtm

102. Egrifta WR Now Available for HIV-Related Lipodystrophy. Gastroenterology Advisor. 2025. https://www.gastroenterologyadvisor.com/news/egrifta-wr-now-available-for-hiv-related-lipodystrophy/

103. Theratechnologies Reports Financial Results for the First Quarter. FirstWord Pharma. 2025. https://firstwordpharma.com/story/5948719

104. PA.CP.PHAR.109 Tesamorelin (Egrifta SV, Egrifta WR). Pennsylvania Health & Wellness. 2025. https://www.pahealthwellness.com/content/dam/centene/Pennsylvania/policies/pharmacy-policies/Tesamorelin%2520_Egrifta%2520SV%2C%2520Egrifta%2520WR_%2520v1.2025.pdf